fig3

Profiling the gut and oral microbiota of hormone receptor-positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin

Figure 3. Samples with a relative abundance of > 30% Streptococcus came from patients who experienced a CB. (A) Heatmap by Bray-Curtis dissimilarity matrix on saliva samples by the top ten genera; (B) further visualization showed this tended to be BL samples. This difference between oral Streptococcus in CB and no-CB group was lost at consecutive time points (C), most likely due to a combination of antibiotic usage and a lower number of EOT samples provided. Mann-Whitney U test was performed on the CB vs. no-CB group where no significance was observed. Antibiotics, categorized by class, taken by patients based on clinical metadata. Not all patients enrolled in the CALADRIO study had complete metadata about antibiotics, which is why the number of patients presented differs from the number of patients enrolled (D). No clustering of gut microbiota data was observed according to CB status, suggesting no overall taxonomic changes (E). Mann-Whitney U was performed to compare the relative abundances of Streptococcus by time point. CB: Clinical benefit; BL: baseline; EOT: end-of-treatment.

Microbiome Research Reports
ISSN 2771-5965 (Online)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/